retatrutide clinical trial results obesity Eli Lilly infiltrates anti-obesity market as Phase III for begins Triple hormone receptor agonist retatrutide

See Important Safety Information, including Boxed Warning, at

These neurons are found in the brain, brainstem, and spinal cord

It is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) not yet approved by the MHRA for use in the UK as of mid-2025

The analysis of subgroups based on the results of 2 randomized controlled trials and supporting data from 4 observational studies suggest that GLP-1RAs can reduce alcohol consumption in some categories of patients [94]

Most studies that link semaglutide with DVT find a possible link with GI complications and rapid weight loss

Now includes our Next-Generation Formula Upgrade